A retrospective analysis of vortioxetine utilization in children and adolescents with major depressive disorder in clinical practice

A retrospective analysis of vortioxetine utilization in children and adolescents with major depressive disorder in clinical practice

Abstract Background Treating depression in children and adolescents has always been a challenge in clinical pharmacotherapy. Vortioxetine, as a new type of antidepressant, is considered to have the potential for use in the treatment of depression in children and adolescents. This study aimed to eval...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xianmei Luo, Shu Yu, Keliang Pan, Lin Cheng, Fan Luo, Handi Zhang, Mingjun Duan, Yajun Zhang
Format:	Article
Language:	English
Published:	BMC 2025-05-01
Series:	BMC Psychiatry
Subjects:	Vortioxetine Major depressive disorder Children Adolescents Retrospective analysis
Online Access:	https://doi.org/10.1186/s12888-025-06983-1
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials
by: Li G, et al.
Published: (2016-02-01)

Effect of vortioxetine versus venlafaxine on cognitive functions in adults with major depressive disorder: A randomized-controlled trial
by: Chayan K. Manna, et al.
Published: (2023-08-01)

Optimizing the diagnosis and treatment of depression in primary care: the emerging role of vortioxetine treatment
by: José Ángel Alcalá, et al.
Published: (2025-07-01)

Efficiency and safety of Vortioxetine in the treatment of depressive disorders in cardiac patients
by: N. V. Filippova, et al.
Published: (2023-06-01)

Comparison of the efficacy of the multimodal serotonergic antidepressants trazodone and vortioxetine in the treatment of patients with endogenous depression: A meta-analysis of double-blind randomized placebo-controlled trials
by: D. S. Danilov
Published: (2017-03-01)

Vortioxetine for depression treatment in hospital setting: experience from a single psychiatric hospital
by: O. V. Limankin, et al.
Published: (2020-10-01)

Post-marketing safety surveillance of vortioxetine hydrobromide: a pharmacovigilance study leveraging FAERS database
by: Ying Zhang, et al.
Published: (2025-02-01)

Vortioxetine in the Treatment of Major Depressive Disorder Among Working Patients in Routine Clinical Practice: An Analysis of a Post-Marketing Surveillance Study in South Korea
by: Moon SW, et al.
Published: (2024-11-01)

The effectiveness of vortioxetine in patients with depression in real clinical practice
by: N. N. Petrova
Published: (2022-10-01)

The effect of vortioxetine on penicillin-induced epileptiform activity in rats
by: Muhammed Nur ÖGÜN, et al.

Anhedonia as a basic syndrome and a target for treatment for depressive disorder
by: G. E. Mazo, et al.
Published: (2019-10-01)

Vortioxetine Can Be Used Safely to Treat Depression After Implantable Cardioverter Defibrillator Implantation for Congenital Long QT Syndrome: A Case Report
by: Makio Yamauchi, et al.
Published: (2025-06-01)

Depression in adolescents with beta-thalassemia major in Erbil city-Iraq
by: Liqaa Habeeb Yousif, et al.
Published: (2023-06-01)

The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis
by: Fu J, et al.
Published: (2016-04-01)

A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system
by: Miao Liu, et al.
Published: (2025-08-01)

Comprehensive analysis of adverse events associated with vortioxetine using the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2025-05-01)

A Grant Report: Examining the Efficacy of Remote Photobiomodulation Therapy in Adolescents with Major Depressive Disorder
by: Adriano Alberti, et al.
Published: (2024-09-01)

Vortioxetine exhibits anti-glioblastoma activity via the PI3K-Akt signaling pathway
by: Huan-Qi Zhang, et al.
Published: (2025-04-01)

Gender differences of neurometabolic and neuroendocrine alternations and its lateralization in adolescents with major depressive disorder
by: Xiaodong Song, et al.
Published: (2024-12-01)

Efficacy and tolerability of vortioxetine monotherapy in SSRI-resistant OCD: a retrospective multicenter study
by: Vassilis Martiadis, et al.
Published: (2025-06-01)

Casein and acryl amide complexation and bio-adhesive polymeric nano micelles influence on vortioxetine dissolution, penetration enhancement and in vivo absorption
by: Samaa Abdullah, et al.
Published: (2024-12-01)

Prevalence and Correlates of Diurnal Mood Variation in Chinese Adolescents with Major Depressive Disorder and Anxiety Symptoms: A Cross-Sectional Study
by: Duan J, et al.
Published: (2025-02-01)

A network analysis of alexithymia, empathy, and suicidal ideation in Chinese adolescents with major depressive disorders
by: Yudong Shi, et al.
Published: (2025-04-01)

Using hierarchical drift diffusion models to elucidate computational mechanisms of reduced reward sensitivity in adolescent major depressive disorder
by: Lei Shen, et al.
Published: (2024-12-01)

Vortioxetine alleviates motor, cognitive and emotional disorders in post-stroke rats by regulating the TLR-2/NF-κB pathway
by: Ziqiang Dong, et al.
Published: (2025-03-01)

Association of the neutrophil-to-platelet ratio with response to electroconvulsive therapy in adolescents with major depressive disorder
by: Dandan Geng, et al.
Published: (2024-11-01)

Assessing a prediction model for depression risk using an early adolescent sample with self‐reported depression
by: Eileen Y. Xu, et al.
Published: (2025-06-01)

The association of cyberbullying with major depressive disorders among Bangladeshi female adolescents: findings from the Bangladesh adolescent health and wellbeing survey 2019-20
by: Syed Toukir Ahmed Noor, et al.
Published: (2025-08-01)

Associations between appetite loss and clinical features as well as inflammatory cytokines in adolescents with major depressive disorder
by: Lewei Liu, et al.
Published: (2025-05-01)

Vortioxetine as an alternative treatment for somatic symptom disorder: case report
by: Naoki Furutani, et al.
Published: (2024-11-01)

Association between sleep disorder and anhedonia in adolescence with major depressive disorder: the mediating effect of stress
by: Xinxin Zhao, et al.
Published: (2024-12-01)

Therapeutic effects of short-term trauma stabilization techniques combined with escitalopram in treating adolescent major depressive disorder: a pilot randomised controlled trial
by: Jiating Xu, et al.
Published: (2025-02-01)

Network analysis of childhood maltreatment and internet addiction in adolescents with major depressive disorder
by: Song Wang, et al.
Published: (2024-11-01)

Disruption of Multimodal Brain Networks and Structural-Functional Coupling in Adolescents with Major Depressive Disorder
by: Wang Y, et al.
Published: (2025-04-01)

Heart rate variability and heart rate asymmetry in adolescents with major depressive disorder during nocturnal sleep period
by: Wanlin Chen, et al.
Published: (2025-05-01)

Alexithymia and self-injury functions as mediators between childhood maltreatment and nonsuicidal self-injury in adolescents with major depressive disorder
by: Yudong Shi, et al.
Published: (2025-07-01)

Associations of non-suicidal self-injury with childhood maltreatment and inflammatory cytokines in adolescents with major depressive disorder
by: Haojie Fan, et al.
Published: (2025-07-01)

Dealing with major depression in general practice
by: C.P. Freeman, et al.
Published: (2012-06-01)

Dealing with major depression in general practice
by: C.P. Freeman, et al.
Published: (2013-08-01)

Correlation of Non-suicidal Self-injury with 25-Hydroxyvitamin D3 and Blood Lipid Levels in Adolescents with Major Depressive Disorder
by: FAN Haojie, LIU Lewei, XIA Lei, TIAN Yinghan, YANG Cheng, HAO Mingru, ZHAO Xin, SHEN Qingqing, MO Daming, GENG Feng, LIU Huanzhong
Published: (2025-02-01)